In contrast, in ERβ2-expressing cells, the regulation of the two unique hub genes (CXCL12 and SIX4) and of nine of the other unique genes (INHBE, GADD45B, RPS7, IFIT3, IGFBP3, JAG2, BCL3, GPR37L1 and KRT80) reportedly favors inhibition of cell death, resistance of BC to endocrine therapy and poor clinical prognosis [65,66,67,68,69,70,71,72,73,74,75]. Here, BCL3 is linked to breast cancer.